# Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-disorder-psychiatric-risk-profile/ > **Published:** 2026-04-01T08:01:01-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:33:09-04:00 > **Clinical Summary:** Explore the cannabis use disorder psychiatric risk profile compared to other substance use disorders in this large retrospective cohort study. --- CED Clinical Relevance  #74Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)[Substance Use Disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/)Psychiatric ComorbidityRisk AssessmentCohort Study Journal The American journal of psychiatry Study Type Cohort Population Human participants Why This Matters This large-scale retrospective analysis challenges prevailing assumptions about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder’s [psychiatric risk](https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/) profile compared to other [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/). The findings suggest CUD may carry lower mental health risks than commonly believed, which has important implications for clinical risk stratification and treatment planning. Clinical Summary Using the TriNetX Research Network, researchers compared mental health outcomes between patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) (CUD) only versus other substance use disorders, employing propensity score matching across 345,903 adult patients per cohort. Adults with isolated CUD showed significantly lower rates of subsequent schizophrenia (0.34% vs 0.42%), depression (1.35% vs 1.74%), and psychotic disorders (0.36% vs 0.52%) compared to those with other SUDs. The study design controls for demographic factors and 24 comorbidities, though residual confounding and the observational nature limit causal inference. Dr. Caplan’s Take “While this data doesn’t minimize CUD’s clinical significance, it does suggest our relative concern about psychiatric sequelae may be disproportionate compared to other substances. I find this useful for contextualizing risk discussions with patients and families.” Clinical Perspective 🧠 Clinicians should interpret these findings as comparative risk data rather than absolute safety assurance for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder. The results support individualized risk assessment and may inform treatment prioritization, though standard [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) principles remain unchanged regardless of substance type. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Association%20of%20Cannabis%20Use%20Disorder%20Versus%20Other%20Substance%20Use%20Disorders%20With%20P...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41776722/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41776722/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Association%20of%20Cannabis%20Use%20Disorder%20Versus%20Other%20Substance%20Use%20Disorders%20With%20P...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41776722/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41776722/](https://pubmed.ncbi.nlm.nih.gov/41776722/) Table of Contents - [FAQ](#FAQ)[Does cannabis use disorder carry the same psychiatric risk as other substance use disorders?](#Does_cannabis_use_disorder_carry_the_same_psychiatric_risk_as_other_substance_use_disorders) - [Are there age-related differences in psychiatric risk between cannabis and other substance use disorders?](#Are_there_age-related_differences_in_psychiatric_risk_between_cannabis_and_other_substance_use_disorders) - [How does having multiple substance use disorders affect psychiatric risk in cannabis users?](#How_does_having_multiple_substance_use_disorders_affect_psychiatric_risk_in_cannabis_users) - [What psychiatric conditions should clinicians monitor most closely in patients with cannabis use disorder?](#What_psychiatric_conditions_should_clinicians_monitor_most_closely_in_patients_with_cannabis_use_disorder) - [How should these findings influence substance use disorder treatment planning?](#How_should_these_findings_influence_substance_use_disorder_treatment_planning) - [Related](#Related) ## FAQ #### Does cannabis use disorder carry the same psychiatric risk as other substance use disorders? No, this large retrospective cohort study found that adults with cannabis use disorder alone had significantly lower risks of developing schizophrenia, depression, and psychotic disorders compared to those with other substance use disorders. The relative risk reductions were substantial, with 19% lower risk for schizophrenia and 22% lower risk for depression. #### Are there age-related differences in psychiatric risk between cannabis and other substance use disorders? Yes, the study examined both adult and pediatric populations separately, suggesting that age may influence the relationship between cannabis use disorder and subsequent psychiatric conditions. However, the study design specifically compared different age groups to account for developmental considerations in substance use outcomes. #### How does having multiple substance use disorders affect psychiatric risk in cannabis users? The study specifically analyzed adults with cannabis use disorder plus another substance use disorder versus those with multiple non-cannabis substance use disorders. This comparison helps clinicians understand whether cannabis adds additional [psychiatric risk](https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/) when combined with other substances. #### What psychiatric conditions should clinicians monitor most closely in patients with cannabis use disorder? Based on this study’s findings, clinicians should monitor for schizophrenia, depression, and psychotic disorders, as these were the specific mental health outcomes measured. While cannabis use disorder showed lower risk than other SUDs, these conditions still occurred and require clinical vigilance. #### How should these findings influence substance use disorder treatment planning? These results suggest that cannabis use disorder may have a different psychiatric risk profile compared to other substance use disorders, potentially informing risk stratification and monitoring approaches. However, clinicians should continue comprehensive psychiatric screening regardless of substance type, as mental health complications can still occur across all substance use disorders. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41776722/”, “about”: “american journal psychiatry cohort association cannabis”, “isPartOf”: “The American journal of psychiatry”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Alcohol And Tobacco Are More Damaging To Users And Society Than Marijuana Is …](https://cedclinic.com/comparative-harm-alcohol-tobacco-cannabis-risks/) This article discusses the comparative societal and health impacts of alcohol, tobacco, and marijuana use. [Read More](https://cedclinic.com/comparative-harm-alcohol-tobacco-cannabis-risks/) [Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/) A detailed analysis of cannabis use disorder compared to other substance use disorders in psychiatric contexts. [Explore Study](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/) [Comparative Clinical Trajectories Across Cannabis‐Related and Nonsubstance‐Related Psychoses](https://cedclinic.com/cannabis-related-psychosis-clinical-trajectories/) This study compares clinical outcomes in cannabis-related psychoses versus non-substance-related psychoses. [Learn More](https://cedclinic.com/cannabis-related-psychosis-clinical-trajectories/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).